Tradestie Institutional Equity Comparison Engine

DRTS vs MPLT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

DRTS Overall Edge

DRTS Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Alpha Tau Medical Ltd. Ordinary Shares (DRTS) driven by superior Momentum & Technical, Options & Structure while MPLT counters with relative strength in Growth & Margin. Fundamentally, DRTS trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus MPLT at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, DRTS sits in CONSOLIDATION (4th %ile IV; Dealer Gamma Walls on Pro) against MPLT sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
DRTS N/M vs MPLT N/M Fwd P/E
Growth & Margin Winner MPLT
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner DRTS
1Y +212.7% vs -51.4% ยท 52W Pos 70% vs 3%
Options & Structure Winner DRTS
CONSOLIDATION (4th %ile IV) vs BREAKDOWN (8th %ile IV)
DRTS NASDAQ
Alpha Tau Medical Ltd. Ordinary Shares
Surgical & Medical Instruments & Apparatus
$12.09
-9.64% 1D
Market Cap $1.2B
1M Return -1.63%
1Y Return +212.73%
Forward P/E N/M
Unified AI Score
43.8 / 100 HOLD
Tech 18.0 Fund 57.0 Flow 72.0 Mom 60.0
MPLT US Equity
MapLight Therapeutics, Inc.
Pharmaceutical Preparations
$6.94
-4.28% 1D
Market Cap $392.9M
1M Return -9.87%
1Y Return -51.4%
Forward P/E N/M
Unified AI Score
50.4 / 100 HOLD
Tech 49.0 Fund 56.0 Flow 64.0 Mom 58.9

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: DRTS +212.73% MPLT -51.4% Spread: +264.13 pp (DRTS Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
DRTS TTM Op. Margin: 0.0% MPLT TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DRTS vs MPLT. Trailing 12-month operating profitability (DRTS 0.0% vs MPLT 0.0%) and valuation multiples (DRTS N/M vs MPLT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: DRTS (3) vs MPLT (2)
Institutional Metric DRTS MPLT Criterion Row Winner
Market Capitalization Scale $1.2B $392.9M Larger Scale DRTS
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -141.7% -111.5% Higher ROE MPLT
52-Week Range Position Momentum 70% ($3โ€“$16) 3% ($6โ€“$40) Stronger Trend DRTS
Beta / 30D Volatility Risk Regime 1.73ฮฒ ยท 62% Vol 1.05ฮฒ ยท 78% Vol Lower Realized Risk DRTS
Unified Institutional Score Composite Signal 43.8 / 100 (HOLD) 50.4 / 100 (HOLD) Higher Composite MPLT

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full DRTS vs MPLT Buy Guide
DRTS CONSOLIDATION
94d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 4th %ile
IV Regime Compressed (<25th %ile)
Live DRTS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MPLT BREAKDOWN
144d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 8th %ile
IV Regime Compressed (<25th %ile)
Live MPLT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither DRTS nor MPLT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.